Новости на английском по уровням

Ozempic and Weight-Loss Drugs Linked to 30 Percent Drop in Breast Cancer Risk

A major study by the University of Pennsylvania found that women taking GLP-1 weight-loss drugs such as Ozempic and Wegovy were about 30 percent less likely to develop breast cancer than those not taking the drugs. The research, published in June 2026 and presented at the American Society of Clinical Oncology annual meeting, examined more than 111,000 women. Scientists say the findings are promising but a clinical trial is needed to confirm the protective effect.